2.

EGFR突变与野生型患者的疗效比较

The efficacy of icotinib in EGFR mutation and wild-type patients

Best response	Mutation [n (%)]	Wild-type [n (%)]	P
Complete response	0 (0)	0 (0)	-
Partial response	21 (17.7)	1 (11.4)	-
Stable disease	11 (30.6)	6 (43.1)	-
Progressive disease	4 (51.6)	6 (45.5)	-
Response rate	58.30%	7.70%	0.001, 7
Disease control rate	88.90%	53.80%	0.007, 2
Median progression-free survival (month)	9.5	2.2	< 0.001
Median overall survival (month)	-	12.6	< 0.001